T/Tn Antigen Vaccine is Effective and Safe in Preventing Recurrence of Advanced Human Breast Carcinoma
| Autor: | Georg F. Springer, Desai Pr, Herta Tegtmeyer, Edward F. Scanlon, S.C. Carlstedt |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Helper T lymphocyte medicine.medical_treatment Breast Neoplasms Pilot Projects Gastroenterology Internal medicine Carcinoma Humans Medicine Cytotoxic T cell Antigens Tumor-Associated Carbohydrate Hypersensitivity Delayed Neoplasm Metastasis Stage (cooking) Survival rate Neoplasm Staging Pharmacology Vaccines business.industry Vaccination Immunotherapy Middle Aged medicine.disease Combined Modality Therapy Surgery Survival Rate Treatment Outcome Female Neoplasm Recurrence Local business Breast carcinoma |
| Zdroj: | Cancer Biotherapy. 9:7-15 |
| ISSN: | 1062-8401 |
| DOI: | 10.1089/cbr.1994.9.7 |
| Popis: | Since 1974, and as of March, 1993, we have used T/Tn antigen vaccine in safe, specific, effective, long-term intradermal vaccination against recurrence of advanced breast carcinoma (CA). Staging is by the pathologic TNM system. Treatment is ad infinitum. Of 19 consecutive breast carcinoma patients vaccinated, six Stage IV, six Stage III, and seven Stage II all survived > 5 years postoperatively. Three Stage III, three Stage IV, and five Stage II patients (i.e., 11) survived > 10 to > 18 years. Five others are alive but have not reached 10 years; three of them have no evidence of disease (NED). Three patients died of CA before reaching 10 years. An additional three breast CA patients are being treated for > 2 years, but, < 5 years postoperatively, they are NED. The vaccination are presented as a delayed-type hypersensitivity reaction with significant inflammation with increase of helper T lymphocytes and decrease of T suppressor/cytotoxic cell ratio. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|